Assenagon Asset Management S.A. Sells 146,183 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assenagon Asset Management S.A. decreased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 90.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,216 shares of the company's stock after selling 146,183 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Amphastar Pharmaceuticals were worth $441,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in shares of Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares during the period. Bridge City Capital LLC lifted its position in shares of Amphastar Pharmaceuticals by 65.3% in the 1st quarter. Bridge City Capital LLC now owns 115,855 shares of the company's stock worth $3,359,000 after acquiring an additional 45,760 shares during the period. Rhumbline Advisers lifted its position in shares of Amphastar Pharmaceuticals by 1.9% in the 1st quarter. Rhumbline Advisers now owns 88,958 shares of the company's stock worth $2,579,000 after acquiring an additional 1,631 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $38,000. Finally, Voloridge Investment Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 16.2% during the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company's stock worth $5,326,000 after buying an additional 19,991 shares during the period. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ:AMPH traded up $0.12 during midday trading on Monday, hitting $24.68. The company had a trading volume of 409,007 shares, compared to its average volume of 491,853. Amphastar Pharmaceuticals, Inc. has a 12 month low of $22.64 and a 12 month high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 8.94, a PEG ratio of 6.40 and a beta of 0.77. The firm has a fifty day simple moving average of $24.77 and a 200 day simple moving average of $29.95.

Wall Street Analyst Weigh In

Several research firms recently commented on AMPH. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of "Hold" and an average price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.